Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

492
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
492
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

488
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
488
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

433
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
433
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

521
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
521
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

321
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
321
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

361
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
361

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

You can read something that is delightful to you: a scoping review of reading interventions in neonatal and paediatric critical care settings.

Cardiology in the young·2026
Same author

Heart Transplant Outcomes in Chemotherapy-Induced vs. Non-Ischemic-Dilated Cardiomyopathy: Pediatric and Adult Recipients in the Ventricular Assist Device Era.

Reviews in cardiovascular medicine·2026
Same author

Predicting 1-Year Mortality After Pediatric Heart Transplantation Using Machine Learning: A Systematic Review and Meta-Analysis.

JACC. Advances·2025
Same author

Pediatric heart-kidney transplantation.

JHLT open·2025
Same author

Pediatric Heart Failure: A Practical Guide for Primary Care Providers Supporting Families Across the Care Continuum.

Children (Basel, Switzerland)·2025
Same author

Recognizing a Few of the Vaccine Preventable Diseases.

Pediatrics in review·2025

Related Experiment Video

Updated: Jan 23, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.3K

An Update on Pediatric Cardiomyopathy.

Swati Choudhry1, Kriti Puri2, Susan W Denfield2

  • 1Department of Pediatrics, Section of Pediatric Cardiology, Texas Children's Hospital, Baylor College of Medicine, 6651 Main St, Houston, TX, 77030, USA. sxchoudh@texaschildrens.org.

Current Treatment Options in Cardiovascular Medicine
|June 26, 2019
PubMed
Summary

Pediatric cardiomyopathies, often genetic, significantly impact children

Keywords:
DilatedHeart failureHypertrophicNon-compactionPediatric cardiomyopathyRestrictive

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.3K
Guidelines for Elective Pediatric Fiberoptic Intubation
11:19

Guidelines for Elective Pediatric Fiberoptic Intubation

Published on: January 17, 2011

18.4K

Related Experiment Videos

Last Updated: Jan 23, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.3K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.3K
Guidelines for Elective Pediatric Fiberoptic Intubation
11:19

Guidelines for Elective Pediatric Fiberoptic Intubation

Published on: January 17, 2011

18.4K

Area of Science:

  • Cardiology
  • Pediatric Medicine
  • Genetics

Background:

  • Pediatric cardiomyopathies are rare but serious heart muscle diseases affecting children.
  • These progressive conditions are frequently caused by genetic mutations leading to myocyte abnormalities.
  • Dilated cardiomyopathy (DCM) is most common (50-60%), followed by hypertrophic cardiomyopathy (HCM) (40%).

Purpose of the Study:

  • To review clinical characteristics and outcomes of primary pediatric cardiomyopathies.
  • To summarize data on dilated (DCM), hypertrophic (HCM), restrictive (RCM), and left ventricular non-compaction (LVNC) cardiomyopathies.
  • To briefly discuss arrhythmogenic cardiomyopathy (ACM), predominantly arrhythmogenic right ventricular cardiomyopathy (ARVC).

Main Methods:

  • Literature review of clinical characteristics and updated outcomes.
  • Synthesis of data on prevalence, etiology, and prognosis.
  • Discussion of current treatment strategies and challenges in pediatric populations.

Main Results:

  • Estimated annual incidence of pediatric cardiomyopathies is 1.1-1.5 per 100,000.
  • Five-year transplant-free survival rates vary: DCM (50%), HCM (90%), RCM (30%), LVNC (60%).
  • Genetic mutations are a dominant factor; current treatments alleviate symptoms but don't prevent sudden death.

Conclusions:

  • Pediatric cardiomyopathies are a significant cause of childhood morbidity and mortality.
  • Dilated and hypertrophic forms are most prevalent, with genetic factors playing a key role.
  • Treatment guidelines are largely based on adult data, with unclear indications for ICD placement in children.